QUOFENIX®
(delafloxacin [as meglumine])
A. MENARINI
HK Reg. No. HK-68500 (15 Dec, 2024)
Composition:3
• Each vial contains delafloxacin meglumine equivalent to 300 mg delafloxacin. After reconstitution each ml contains 25 mg delafloxacin
Indication:3*
• Quofenix is indicated for the treatment of the following infections in adults:
- Acute bacterial skin and skin structure infections (ABSSSI)
- Community-acquired pneumonia (CAP)
* Because of the risk of prolonged, disabling and potentially irreversible serious adverse drug reactions, this product must only be prescribed when other antibiotics that are commonly recommended for the infection are inappropriate. This applies to all indications listed above
References
1. Therapeutic Goods Administration, Australia. Product Information. 18 March 2024. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2022-PI-01599-1&d=20250103172310101. [Accessed 3 January 2025]. 2. European Medicines Agency. Summary of Product Characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2023/20231201161202/anx_161202_en.pdf. [Accessed 3 January 2025]. 3. EMC. Quofenix 300 mg powder for concentrate for solution for infusion SmPC. Available from: https://www.medicines.org.uk/emc/product/11481/smpc#about-medicine. [Accessed 3 January 2025]. 4. European Medicines Agency. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. [Accessed 3 January 2025].
